Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL

This study was registered at www.clinicaltrials.gov as #NCT02077166.

Source: Blood - September 25, 2019 Category: Hematology Authors: Goy, A., Ramchandren, R., Ghosh, N., Munoz, J., Morgan, D. S., Dang, N. H., Knapp, M., Delioukina, M., Kingsley, E., Ping, J., Beaupre, D. M., Neuenburg, J. K., Ruan, J. Tags: Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research